Your browser is no longer supported. Please, upgrade your browser.
SELB Selecta Biosciences, Inc. daily Stock Chart
Selecta Biosciences, Inc.
Index- P/E- EPS (ttm)-1.12 Insider Own0.30% Shs Outstand94.72M Perf Week-6.16%
Market Cap248.49M Forward P/E- EPS next Y-0.48 Insider Trans-0.59% Shs Float73.07M Perf Month-31.16%
Income-62.90M PEG- EPS next Q-0.01 Inst Own65.90% Short Float9.70% Perf Quarter44.21%
Sales6.70M P/S37.09 EPS this Y58.40% Inst Trans14.88% Short Ratio3.27 Perf Half Y19.13%
Book/sh-0.09 P/B- EPS next Y-14.30% ROA-91.50% Target Price- Perf Year64.07%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.28 - 4.83 Perf YTD15.13%
Dividend- P/FCF- EPS past 5Y5.10% ROI-192.10% 52W High-43.27% Beta1.39
Dividend %- Quick Ratio2.50 Sales past 5Y17.00% Gross Margin- 52W Low114.06% ATR0.31
Employees27 Current Ratio2.50 Sales Q/Q- Oper. Margin- RSI (14)41.06 Volatility6.80% 12.21%
OptionableYes Debt/Eq- EPS Q/Q34.00% Profit Margin- Rel Volume0.86 Prev Close2.84
ShortableYes LT Debt/Eq- EarningsMay 07 BMO Payout- Avg Volume2.17M Price2.74
Recom1.70 SMA20-12.51% SMA50-14.66% SMA2006.66% Volume1,846,373 Change-3.52%
Jun-12-20Downgrade Stifel Buy → Hold
Apr-28-20Initiated H.C. Wainwright Buy $8
Jan-29-20Initiated Cantor Fitzgerald Overweight $10
Jan-21-20Initiated William Blair Outperform
Jun-27-18Initiated Janney Buy $33
Mar-30-17Reiterated UBS Buy $26
Jun-23-20 04:05PM  
Jun-19-20 12:22PM  
Jun-18-20 08:30AM  
Jun-16-20 11:30AM  
Jun-15-20 08:00AM  
Jun-12-20 12:24PM  
Jun-11-20 05:15PM  
May-29-20 08:52AM  
May-26-20 08:00AM  
May-20-20 01:06PM  
May-18-20 10:04AM  
May-12-20 12:49PM  
May-08-20 02:30PM  
May-07-20 07:30AM  
May-06-20 12:04PM  
May-05-20 08:00AM  
Apr-30-20 08:00AM  
Apr-28-20 08:00AM  
Apr-07-20 08:00AM  
Mar-31-20 08:12AM  
Mar-12-20 08:00AM  
Mar-05-20 08:00AM  
Mar-03-20 03:00PM  
Feb-23-20 07:10AM  
Feb-18-20 08:00AM  
Dec-19-19 08:25AM  
Dec-16-19 07:53AM  
Nov-22-19 10:54AM  
Nov-21-19 08:00AM  
Nov-15-19 11:17PM  
Nov-12-19 08:00AM  
Nov-11-19 09:00AM  
Nov-08-19 08:00AM  
Nov-01-19 08:09AM  
Oct-24-19 08:00AM  
Oct-23-19 10:48AM  
Sep-04-19 08:00AM  
Sep-03-19 02:21PM  
Sep-02-19 04:55PM  
Aug-08-19 08:00AM  
Aug-07-19 07:35AM  
Aug-01-19 08:00AM  
Jul-31-19 08:00AM  
Jul-15-19 08:00AM  
Jun-28-19 08:38AM  
Jun-26-19 10:15AM  
Jun-21-19 08:39AM  
Jun-20-19 04:05PM  
Jun-15-19 10:36AM  
Jun-12-19 08:00AM  
May-30-19 08:00AM  
May-23-19 01:46AM  
May-09-19 08:00AM  
May-02-19 08:00AM  
Apr-16-19 04:05PM  
Apr-04-19 05:54AM  
Apr-02-19 08:00AM  
Mar-29-19 08:00AM  
Mar-26-19 04:05PM  
Mar-20-19 04:05AM  
Mar-15-19 08:00AM  
Mar-08-19 08:00AM  
Mar-06-19 04:01PM  
Jan-31-19 04:19PM  
Jan-23-19 09:19AM  
Jan-22-19 04:01PM  
Jan-07-19 08:45AM  
Jan-04-19 06:08AM  
Jan-03-19 04:11PM  
Dec-06-18 10:42AM  
Dec-03-18 08:00AM  
Nov-20-18 09:52PM  
Nov-19-18 09:00AM  
Nov-15-18 02:19PM  
Nov-08-18 08:00AM  
Nov-06-18 08:00AM  
Nov-01-18 08:00AM  
Oct-24-18 02:14PM  
Oct-23-18 07:05AM  
Oct-18-18 02:07PM  
Oct-16-18 08:00AM  
Oct-01-18 09:32AM  
Sep-27-18 02:48PM  
Sep-25-18 08:00AM  
Sep-20-18 08:00AM  
Sep-10-18 08:00AM  
Aug-31-18 08:00AM  
Aug-14-18 01:35PM  
Aug-08-18 08:00AM  
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that in Phase II clinical trials for the treatment of chronic refractory gout. It is also developing SEL-403, which is in Phase I clinical trials for the treatment of patients with malignant pleural or peritoneal mesothelioma. In addition, the company engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., and BIND Therapeutics, Inc.; and a strategic partnership with Asklepios BioPharmaceutical, Inc. for the development, manufacture, and commercialization of targeted therapeutics for adeno-associated virus gene therapies in the areas of high medical need. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARABE TIMOTHY CDirectorJun 24Option Exercise1.4632,84047,946121,013Jun 26 04:21 PM
Brunn CarstenPresident and CEOJun 02Sale3.863,25312,55786,162Jun 03 04:42 PM
Brunn CarstenPresident and CEOJun 01Option Exercise0.0010,938089,415Jun 03 04:42 PM
BARABE TIMOTHY CDirectorMar 17Buy2.005,00010,00088,173Mar 19 05:16 PM
Brunn CarstenPresident and CEOMar 03Sale3.863,37413,01178,477Mar 03 04:25 PM
Brunn CarstenPresident and CEOMar 01Option Exercise0.0010,937081,851Mar 03 04:25 PM
Johnston Lloyd P.COO and SVP, R&DJan 16Option Exercise0.475,1282,41016,734Jan 21 05:21 PM
Brunn CarstenPresident and CEODec 02Sale1.5314,27221,80970,914Dec 03 04:20 PM
Brunn CarstenPresident and CEODec 01Option Exercise0.0043,750085,186Dec 03 04:20 PM
SPRINGER TIMOTHY ADirectorAug 14Buy1.7410,00017,41586,418Aug 16 04:18 PM
BARABE TIMOTHY CDirectorAug 13Buy1.7210,00017,20017,492Aug 15 04:19 PM
Johnston Lloyd P.COO and SVP, R&DJul 23Option Exercise0.4710,0004,70011,606Jul 25 04:15 PM